Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.

Preventing breast cancer will require the development of targeted strategies that can effectively block disease progression. Tamoxifen and aromatase inhibitors are effective in addressing estrogen receptor-positive (ER(+)) breast cancer development, but estrogen receptor-negative (ER(-)) breast cancer remains an unmet challenge due to gaps in pathobiologic understanding. In this study, we used reverse-phase protein array to identify activation of Src kinase as an early signaling alteration in premalignant breast lesions of women who did not respond to tamoxifen, a widely used ER antagonist for hormonal therapy of breast cancer. Src kinase blockade with the small-molecule inhibitor saracatinib prevented the disorganized three-dimensional growth of ER(-) mammary epithelial cells in vitro and delayed the development of premalignant lesions and tumors in vivo in mouse models developing HER2(+) and ER(-) mammary tumors, extending tumor-free and overall survival. Mechanistic investigations revealed that Src blockade reduced glucose metabolism as a result of an inhibition in ERK1/2-MNK1-eIF4E-mediated cap-dependent translation of c-Myc and transcription of the glucose transporter GLUT1, thereby limiting energy available for cell growth. Taken together, our results provide a sound rationale to target Src pathways in premalignant breast lesions to limit the development of breast cancers.

[1]  W. Messersmith,et al.  Current status of SRC inhibitors in solid tumor malignancies. , 2011, The oncologist.

[2]  K. Korach,et al.  Tamoxifen versus aromatase inhibitors for breast cancer prevention. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Z. Nahleh,et al.  Glut-1 Expression Correlates with Basal-like Breast Cancer. , 2011, Translational oncology.

[4]  C. Dang,et al.  MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities , 2009, Clinical Cancer Research.

[5]  M. Cazzaniga,et al.  Breast Cancer Chemoprevention: Old and New Approaches , 2012, Journal of biomedicine & biotechnology.

[6]  C. Dang,et al.  Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc* , 2000, The Journal of Biological Chemistry.

[7]  S. Ambudkar,et al.  Saracatinib (AZD0530) is a potent modulator of ABCB1‐mediated multidrug resistance in vitro and in vivo , 2013, International journal of cancer.

[8]  Hanna Y. Irie,et al.  Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment , 2009, Nature.

[9]  Jayanta Debnath,et al.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.

[10]  Y. Dor,et al.  Active Src Elevates the Expression of β-Catenin by Enhancement of Cap-Dependent Translation , 2005, Molecular and Cellular Biology.

[11]  F. Stossi,et al.  Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. , 2006, Molecular endocrinology.

[12]  W. Muller,et al.  Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis , 2011, Proceedings of the National Academy of Sciences.

[13]  Jayanta Debnath,et al.  Modelling glandular epithelial cancers in three-dimensional cultures , 2005, Nature Reviews Cancer.

[14]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[15]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[16]  R. Nicholson,et al.  Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells , 2006, Breast Cancer Research and Treatment.

[17]  Robert J. Gillies,et al.  Causes and Consequences of Increased Glucose Metabolism of Cancers , 2008, Journal of Nuclear Medicine.

[18]  N. Sonenberg,et al.  mRNA translation and energy metabolism in cancer: the role of the MAPK and mTORC1 pathways. , 2011, Cold Spring Harbor symposia on quantitative biology.

[19]  Mark C. Pierce,et al.  High-Resolution Microendoscopy for the Detection of Cervical Neoplasia in Low-Resource Settings , 2012, PloS one.

[20]  D. Gerber,et al.  Targeted therapies: a new generation of cancer treatments. , 2008, American family physician.

[21]  J. Graff,et al.  eIF-4E expression and its role in malignancies and metastases , 2004, Oncogene.

[22]  Jun Li,et al.  TCPA: a resource for cancer functional proteomics data , 2013, Nature Methods.

[23]  J. Baselga,et al.  Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors , 2010, Clinical Cancer Research.

[24]  Mithat Gonen,et al.  18F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical Analysis , 2010, Journal of Nuclear Medicine.

[25]  Hua Guo,et al.  Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways , 2011, Nature Medicine.

[26]  G. Mills,et al.  Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo , 2012, Clinical Cancer Research.

[27]  P. Brown,et al.  Targeted Therapy for Breast Cancer Prevention , 2013, Front. Oncol..

[28]  D. Shalloway,et al.  Apoptosis of estrogen‐receptor negative breast cancer and colon cancer cell lines by PTPα and src RNAi , 2008, International journal of cancer.

[29]  R. Clarke,et al.  MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer , 2014, Molecular Cancer.

[30]  J. Slingerland,et al.  Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy , 2013, Nature Reviews Cancer.

[31]  Alexandros D. Polydorides,et al.  Discrimination of Benign and Neoplastic Mucosa with a High-Resolution Microendoscope (HRME) in Head and Neck Cancer , 2012, Annals of Surgical Oncology.

[32]  Chi V Dang,et al.  Links between metabolism and cancer. , 2012, Genes & development.

[33]  R. Cardiff,et al.  Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.

[34]  R. Airley,et al.  Could GLUT12 be a Potential Therapeutic Target in Cancer Treatment? A Preliminary Report , 2015, Journal of Cancer.

[35]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[36]  M. Hung,et al.  14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. , 2009, Cancer cell.

[37]  Y. Dor,et al.  Activated pp60c-Src Leads to Elevated Hypoxia-inducible Factor (HIF)-1α Expression under Normoxia* , 2002, The Journal of Biological Chemistry.

[38]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[40]  L. Brinton,et al.  Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years , 2009, Cancer Epidemiology Biomarkers & Prevention.

[41]  F. Zhao.  Biology of Glucose Transport in the Mammary Gland , 2014, Journal of Mammary Gland Biology and Neoplasia.

[42]  Gordon B. Mills,et al.  Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer , 2007 .

[43]  V. Seewaldt,et al.  Metabolic Syndrome and Breast Cancer Risk: Is There a Role for Metformin? , 2011, Current breast cancer reports.

[44]  J. Best,et al.  Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer , 2005, Journal of cellular physiology.

[45]  L. Foster,et al.  Protein synthesis rate is the predominant regulator of protein expression during differentiation , 2013, Molecular systems biology.

[46]  B. Gusterson,et al.  Dasatinib inhibits mammary tumour development in a genetically engineered mouse model , 2013, The Journal of pathology.

[47]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[48]  C. Ulrich,et al.  Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. , 2012, Cancer research.

[49]  Nehmat Houssami,et al.  Review of Preoperative Magnetic Resonance Imaging (MRI) in Breast Cancer: Should MRI Be Performed on All Women with Newly Diagnosed, Early Stage Breast Cancer? , 2009, CA: a cancer journal for clinicians.

[50]  Gordon B Mills,et al.  Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. , 2007, The Journal of clinical investigation.

[51]  D. Altman,et al.  The benefits and harms of breast cancer screening: an independent review , 2012, British Journal of Cancer.

[52]  Zhenlin Ju,et al.  Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo , 2011, Breast Cancer Research and Treatment.

[53]  L. Lashinger,et al.  Calorie restriction and cancer prevention: a mechanistic perspective , 2013, Cancer & metabolism.

[54]  Xiao Wang,et al.  Needle-based fluorescence endomicroscopy via structured illumination with a plastic, achromatic objective , 2013, Journal of biomedical optics.

[55]  M. Barone,et al.  Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells , 2012, Oncogene.

[56]  A. Welm,et al.  Modulation of Glucose Transporter 1 (GLUT1) Expression Levels Alters Mouse Mammary Tumor Cell Growth In Vitro and In Vivo , 2011, PloS one.